CSF Aβ42, Tau and phosphorylated Tau, APOE ɛ4 allele and MCI type in progressive MCI

Herukka, Sanna-Kaisa; Helisalmi, Seppo; Hallikainen, Merja; Tervo, Susanna; Soininen, Hilkka; Pirttilä, Tuula

doi:10.1016/j.neurobiolaging.2006.02.001

« Previous Next »Neurobiology of Aging
Volume 28, Issue 4 , Pages 507-514, April 2007

CSF Aβ42, Tau and phosphorylated Tau, APOE ɛ4 allele and MCI type in progressive MCI

Sanna-Kaisa Herukka
- Department of Neuroscience and Neurology, Brain Research Unit, Clinical Research Center, Mediteknia, University of Kuopio, 70211 Kuopio, Finland
- Corresponding author. Tel.: +358 17 163213; fax: +358 17 162048.
Seppo Helisalmi
- Department of Neuroscience and Neurology, Brain Research Unit, Clinical Research Center, Mediteknia, University of Kuopio, 70211 Kuopio, Finland
Merja Hallikainen
- Department of Neuroscience and Neurology, Brain Research Unit, Clinical Research Center, Mediteknia, University of Kuopio, 70211 Kuopio, Finland
Susanna Tervo
- Department of Neuroscience and Neurology, Brain Research Unit, Clinical Research Center, Mediteknia, University of Kuopio, 70211 Kuopio, Finland
Hilkka Soininen
- Department of Neuroscience and Neurology, Brain Research Unit, Clinical Research Center, Mediteknia, University of Kuopio, 70211 Kuopio, Finland
- Department of Neurology, Kuopio University Hospital, 70211 Kuopio, Finland
Tuula Pirttilä
- Department of Neuroscience and Neurology, Brain Research Unit, Clinical Research Center, Mediteknia, University of Kuopio, 70211 Kuopio, Finland
- Department of Neurology, Kuopio University Hospital, 70211 Kuopio, Finland

Received 23 June 2005; received in revised form 20 December 2005; accepted 9 February 2006.

Abstract

Background

The patients with mild cognitive impairment (MCI) have an elevated risk for Alzheimer's disease (AD). Especially the amnestic MCI is seen as prodrome of AD. Apolipoprotein E (APOE) ɛ4 allele, abnormal CSF Aβ42, Tau and phosphorylated Tau (phospho-Tau) levels are associated with elevated risk for AD.

Methods

APOE genotyping was done by PCR based method and baseline CSF Aβ42, Tau and phospho-Tau were measured by ELISA from 60 controls and 79 MCI patients.

Results

Thirty-three MCI patients developed dementia during an average of 3.5 years follow-up. CSF Aβ42 was decreased and Tau and phospho-Tau were increased in the progressive MCI patients. The APOE ɛ4 allele was more frequent in the progressive MCI patients. The APOE ɛ4 allele showed a dose dependent association to the Aβ42 levels in the progressive MCI patients and to all of the markers in controls.

Conclusions

Decreased CSF Aβ42 and elevated Tau or phospho-Tau together with APOE ɛ4 allele are highly predictive for the dementia in MCI patients with amnestic or executive symptoms.

Keywords: Alzheimer's disease, Mild cognitive impairment, Aβ42, Tau, Phosphorylated Tau, Apolipoprotein E